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Primary gastric small cell carcinoma is a rare and aggressive malignant disease with a poor prognosis that was first
reported in 1976 by Matsusaka et al. The incidence is very low and the clinicopathological features are similar to
those of small cell lung carcinoma.
We herein report a case of successful treatment by combination chemotherapy consisting of irinotecan
hydrochloride and cisplatin for primary gastric small cell carcinoma. The patient was a 71-year-old male who was
admitted to a local hospital with anemia. Gastrointestinal endoscopy revealed the presence of advanced gastric
carcinoma at the upper region of the stomach. The patient underwent surgery, and the pathological diagnosis was
small cell carcinoma due to the presence of the typical features of small round cells with scant cytoplasm that were
positive for synaptophysin and chromogranin A in the resected specimen. The patient underwent subsequent
combination chemotherapy, which provided him with over 1 year of survival and a good quality of life. We also
present a review of the literature regarding chemotherapy for primary gastric small cell carcinoma.
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Gastric carcinoma is a widespread malignant disease, and
the worldwide mortality and incidence rates are 6.4 and
8.7 per 100,000, respectively [1]. These rates are particu-
larly high in Japan (27.3 and 60.4 per 100,000, respectively)
[2]. Gastric small cell carcinoma (GSCC) was first de-
scribed as a subtype of gastric carcinoma in 1976 by
Matsuzaka et al. [3]. Currently, GSCC is defined as one of
the neuroendocrine tumors (NETs) according to the
World Health Organization classification. The biological
characteristics and clinicopathological features of GSCC
are similar to those of small cell lung carcinoma (SCLC)
[4-6], but GSCC is known to be more aggressive and ma-
lignant compared to SCLC because GSCC is more resist-
ant to chemotherapy [6]. Effective treatment strategies for
GSCC have not yet been established, because it is very
rare, with an incidence of about 0.02% of all gastric* Correspondence: funa84@med.nagoya-cu.ac.jp
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reproduction in any medium, provided the orcarcinomas, even in Japan. We believe that surgery and
subsequent systemic chemotherapy represent an effective
therapeutic approach for GSCC. Several reports have
recommended using the same therapeutic strategies as
those used for SCLC [6,7]. Standard chemotherapy for
SCLC consisted of VP-16 and cisplatin (CDDP) for a long
time [8]. Recently, combination irinotecan hydrochloride
(CPT-11) and CDDP chemotherapy has been shown to be
more effective for SCLC based on the results of phase II
and phase III clinical trials [9-11]. Therefore, we used
combination CPT-11 and CDDP chemotherapy to treat
the present patient.
We herein report a case with advanced GSCC that
was successfully treated by surgery and subsequent com-
bination CPT-11 and CDDP chemotherapy.Case presentation
A 71-year-old Japanese male went to a local hospital for
postoperative follow-up of colonic carcinoma. Then
anemia was noted, and gastrointestinal endoscopy re-
vealed a large ulcerated tumor around the esophagogastrictral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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oma, and he was admitted to Nagoya City University Hos-
pital for curative treatment. His family history was
unremarkable, and medical history included acute myo-
cardial infarction, bladder carcinoma, and colon carcin-
oma. Laboratory data were within normal limits except for
anemia indicated by a hemoglobin (Hb) level of 9.4 g/dL
(normal range: 13.2 g/dL < Hb < 17.2 g/dL). Serum levels
of carcinoembryonic antigen (CEA) and carbohydrate
antigen 19–9 (CA19-9) were also within normal limits:
1.6 ng/mL (normal range <3.5 ng/mL) and 3.7 U/mL
(normal range <37 U/mL), respectively. On computed
tomography (CT), the tumor appeared as a thickening of
the gastric wall with metastasis to perigastric lymph nodes
(LN) (Figure 1A). Re-examination with gastrointestinal
endoscopy revealed a Borrmann type III tumor locatedFigure 1 Tumor location and form. Abdominal computed tomography (
(white arrow) and lymph node swelling (dotted arrow) before surgery (A).
tumor that measured approximately 100 mm in diameter was located arouaround the esophagogastric junction, which was diagnosed
as GSCC upon histological examination of a biopsy speci-
men at our hospital. After providing informed consent,
and following a sufficiently detailed explanation about his
disease, the patient wished to undergo surgery. Surgical re-
section by proximal gastrectomy was performed. While
total gastrectomy is the standard treatment for such cases,
proximal gastrectomy was selected during surgery, be-
cause his small bowel, which was one lump due to previ-
ous surgery, could not be elevated to allow Rou-en-Y
reconstruction.
Resected specimens showed a Borrmann type III
tumor that measured approximately 100 mm in diam-
eter around the esophagogastric junction (Figure 1B).
Histopathologic examination revealed that the tumor
consisted of small cancer cells with dense chromatinCT) scans showed carcinoma at the esophagogastric junction
Macroscopic findings of the resected stomach: a Borrmann type III
nd the esophagogastric junction (B).
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cells were positive for synaptophysin (Figure 2B) and
chromogranin A (Figure 2C). The final histological
diagnosis was GSCC. The pathological stage was IIIA
(T3, N1, M0) according to the classification proposed
by the Japanese Gastric Cancer Association [12].Figure 2 Microscopic examination of the tumor. Hematoxylin
and eosin staining demonstrated small cells with hyperchromatic
nuclei and scant cytoplasm (x200) (A). The tumor cells were positive
for synaptophysin (B) and chromogranin A (x200) (C).After obtaining informed consent from the patient, we
started the systemic chemotherapy with CPT-11 and
CDDP. On day 1, CPT-11 (60 mg/m2) was administered,
followed by administration of CDDP (80 mg/m2) over 2
hours with adequate hydration. The same dose of CPT-11
was administered on day 15, and this regimen was re-
peated every 4 weeks. Although NCI-CTC grade 2 febrile
neutropenia and diarrhea and grade 1 nausea were ob-
served, these side effects were resolved following phar-
macologic intervention with G-CSF and antidiarrheal
medications. After three courses, the patient declined fur-
ther chemotherapy due to unbearable side effects. After
12 months (4 months after chemotherapy was stopped),
his CEA level increased from 1.6 ng/mL to 12 ng/mL.
Cancer recurrence was confirmed in a regional lymph
node on CT (Figure 3A). Although we suggested re-Figure 3 Postoperative course. Five months after the last course
of chemotherapy, computed tomography (CT) scans revealed a
recurrent regional lymph node (arrow) but no recurrence in the liver
(A). A contemporary gastrointestinal endoscopy revealed
hemorrhage from an esophagus longitudinal ulcer, but no
carcinoma recurrence was apparent in the esophagus (B).
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treatment. Fourteen months after surgery, the patient died
of hemorrhage due to esophageal ulcer and subsequent as-
piration pneumonia (Figure 3B).
Discussion
Small cell carcinoma is a malignant disease that is fre-
quently observed in the lung [5]. While extrapulmonary
small cell carcinoma has been reported in the gastrointes-
tinal tract, head, neck, urinary tract, and genitals [13,14],
incidence of extrapulmonary small cell carcinoma is much
lower than that of SCLC. Among these cancers, primary
GSCC is extremely rare. Matsusaka et al. first reported
GSCC in 1976, and revealed that the incidence was less
than 0.1% of all gastric carcinomas in Japan, even though
the incidence of gastric adenocarcinoma in Japan is much
higher than in other countries [3].
It is generally difficult to diagnose GSCC preoperatively.
Kusayanagi et al. reported that only 40% of patients with
GSCC were diagnosed correctly before surgery [15]. This
may be due to the fact that carcinoma cells can differenti-
ate in many aspects. Matsui et al. also suggested that small
cell carcinomas originate from totipotent primitive cells,
which can result in dual or multiple differentiation into a
mixture of small neoplastic cells, squamous cells, and ade-
nocarcinomatous cells [16]. Furthermore, tumor cells may
not be detectable in biopsy specimens, because GSCC pro-
liferates in the submucosal layer in many cases. In the
present case, adenocarcinoma was first diagnosed at a
local hospital. however, re-examination at our hospital en-
abled a correct diagnosis by cell morphology and immu-
nohistochemical findings.
Immunohistochemical examination is well known to be
valuable for the diagnosis of GSCC. GSCC is unique in its
positive reactions to synaptophysin and chromogranin A,
although 10-20% of GSCCs demonstrate negative reac-
tions for these tumor markers [17]. Histologically, the fea-
tures of GSCC are similar to those of SCLC: they have a
scanty cytoplasm and small-sized oval nuclei with incon-
spicuous nucleoli [18,19]. Therefore, the final diagnosis of
GSCC should be based on both morphologic features and
immunohistochemical reactions. In the present patient,
the final diagnosis of GSCC was achieved due to positivity
for both markers and histopathologic characteristics simi-
lar to SCLC in the resected specimen.
Like SCLC, GSCC is an aggressive disease and the clin-
ical course is generally very poor. Previous reports re-
vealed that almost every patient with GSCC dies within 1
year [6,15], because GSCC shows a high incidence of
vasculolymphatic invasion, marked deep infiltration, and
distant metastases at diagnosis [16,20]. Unfortunately,
there is no standard effective treatment strategy for GSCC.
Various treatment modalities have been proposed includ-
ing surgery, chemotherapy, radiation therapy, and variouscombination of the above [15,20]. Although surgery
and/or adjuvant chemotherapy have been evaluated in
several studies, the results have been unsatisfactory
[6,21-23]. Although the effects of the treatment based
on radiation therapy for esophagus or thyroid small cell
carcinomas were reported [24,25], radiation therapy for
GSCC has not been reported. A few reports revealed
that surgical resection appeared to be effective, with
survival ranging from 9 months to more than 5 years
for patients with GSCC limited to the stomach
[3,26,27]. In contrast, in another report, massive hepatic
metastases occurred in a short period in a case with
early-stage disease, and the patient died within 6
months after definitive surgery [28]. Most patients with
GSCC receive combination therapy consisting of sur-
gery and subsequent chemotherapy, similar to that used
for conventional gastric cancer, which involves 5-FU-
based chemotherapy [6]. Nevertheless, no standard
treatment strategy has been established for GSCC due
to insufficient efficacy. Furthermore, the prognosis in
GSCC is poorer than that for gastric adenocarcinoma,
particularly in patients with advanced-stage diseases:
the reported median survival for GSCC is 7 months
[6,7,16,28]. Treatment of GSCC with chemotherapy reg-
imens used in SCLC may be more effective than other
regimens. In fact, some reports have revealed that some
SCLC chemotherapy regimens are also effective against
GSCC [4,5,29]. The most commonly used combination
chemotherapy regimen for patients with SCLC is
etoposide and CDDP [8]. This regimen yields an overall
response rate of 80-95% in patients with limited disease
and 60-80% in those with extensive disease [30]. Re-
cently, combination CPT-11 and CDDP chemotherapy
has also been shown to be effective for SCLC. The re-
sults of a phase III trial that compared CPT-11 and
CDDP with CDDP and etoposide indicated that the
overall response rate in the CPT-11 and CDDP group
was significantly higher than that in the CDDP and
etoposide group. Moreover, the median survival rate
was 12.8 months in the CPT-11 and CDDP group com-
pared to 9.4 months in the CDDP and etoposide group
[11]. Based on the results of this trial, we elected to use
a combination CPT-11 and CDDP regimen in the
present patient. After three cycles of treatment, the pa-
tient experienced National Cancer Institute’s Common
Toxicity Criteria (NCI-CTC) grade 2 febrile neutro-
penia and diarrhea, and grade 1 nausea. The patient was
sensitive to these side effects and refused further
chemotherapy or alternate therapy. However, his dur-
ation of response and progression-free survival contin-
ued for approximately 1 year. Although previous reports
revealed that almost all patients die within 6 months of
being diagnosed with GSCC [6,7,15,16], this patient sur-
vived for longer than 1 year with a satisfactory quality of
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esophageal ulcer and subsequent aspiration pneumonia.
It was not determined whether the esophageal ulcer was
due to disease recurrence. However, recurrence was not
observed in the esophageal mucosa, and no recurrence
was present in the liver. If he had undergone continu-
ous chemotherapy, he may have survived for a longer
time.
Conclusions
Because the incidence of GSCC is very low, no standard
treatment strategy has been established. Indeed, effective
surgical treatment is needed and subsequent intensive
chemotherapy should be considered to promote long-
term survival. Combination chemotherapy consisting of
CPT-11 and CDDP appears to be effective for the treat-
ment of primary GSCC. Further trials and experience in
additional cases are required to fully evaluate the efficacy
of this CPT-11 and CDDP regimen and to help establish
the best treatment strategy for patients with GSCC.
Consent
Written informed consent was obtained from the pa-
tient’s family for the publication of this case report and
any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
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